Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X
  • Latest News
  • Most Popular
View All | Scroll Down Scroll Up

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/22/2013

Company Name Symbol %Change
ALLIANCE FIB AFOP
9.31%
SONIC FOUNDR SOFO
7.77%
VELTI PLC OR VELT
7.58%
TRI TECH HOL TRIT
6.62%
A M R CP AAMRQ
4.52%

Zacks Rank #1 Strong Buys

Analyst Blog

Print
Share

Hospira to Acquire Javelin Pharma

by Zacks Equity Research

April 20, 2010 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.


Recently, Hospira ( HSP - Analyst Report ) announced its intention to acquire Javelin Pharmaceuticals ( ) for $2.20 per share or approximately $145 million. Hospira expects to initiate the tender offer for all the outstanding shares of Javelin shortly.
The acquisition of Javelin will provide Hospira with access to Javelin’s lead product candidate, Dyloject, a post-operative pain management drug. The drug is awaiting approval from the US Food and Drug Administration (FDA). A final decision is likely by October 3, 2010.
As a non-opioid analgesic, Dyloject scores over traditional intravenous opioids, which are associated with significant adverse events in pain management. Hospira will gain global rights to Dyloject other than in Europe, where rights are licensed to a third party.
Hospira plans to market the product in the US, Canada, Latin America and the Asia-Pacific region, where it also markets Precedex, Hospira's proprietary sedation agent. Since both Precedex and Dyloject are marketed to anesthesiologists, Hospira will be able to leverage its Precedex sales force to promote Dyloject.
In December 2009, Myriad Pharmaceuticals (MYRX) had decided to acquire Javelin in a stock swap deal. However, Javelin decided to terminate this agreement in April 2010. The termination will result in Javelin paying $4.4 million to Myriad in the form of a termination fee and other expenses incurred by Myriad related to the merger.
To meet these expenses and repay its outstanding debt burden, Javelin has entered into a loan agreement with Hospira under which the former may borrow funds up to $4.5 million prior to closing of the merger.
We believe Dyloject, on successful commercialization, will be a good addition to Hospira’s product portfolio and will help boost revenues. We are currently Neutral on Hospira.

Read the full reports :

Email Print Share Rate Pos Rate Neg

Disclosure / Disclaimer Link
Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.
Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.